NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.06 +0.06 (+0.08%) GOLD FUTURES
2,332.90 +21.90 (+0.95%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,420.91 -2,039.47 (-4.21%)
Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
- GlobeNewswire
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024. Details of the panel discussion are as follow: BTIG Obesity Health ForumPanel Title: CB1 Axis Therapies for ObesityDate: Wednesday, May 8, 2024Presentation Time: 3:00 p.m. ET
- GlobeNewswire
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002)
- GlobeNewswire
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC’s Phase 1 China study indicates differentiation from PADCEV NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002),
